Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network.

Tan X, Banerjee P, Liu X, Yu J, Gibbons DL, Wu P, Scott KL, Diao L, Zheng X, Wang J, Jalali A, Suraokar M, Fujimoto J, Behrens C, Liu X, Liu CG, Creighton CJ, Wistuba II, Kurie JM.

J Clin Invest. 2018 Jul 2;128(7):3198. doi: 10.1172/JCI122740. Epub 2018 Jul 2. No abstract available.

2.

LMO1 functions as an oncogene by regulating TTK expression and correlates with neuroendocrine differentiation of lung cancer.

Du L, Zhao Z, Suraokar M, Shelton SS, Ma X, Hsiao TH, Minna JD, Wistuba I, Pertsemlidis A.

Oncotarget. 2018 Jul 3;9(51):29601-29618. doi: 10.18632/oncotarget.25642. eCollection 2018 Jul 3.

3.

Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer.

Gomez DR, Byers LA, Nilsson M, Diao L, Wang J, Li L, Tong P, Hofstad M, Saigal B, Wistuba I, Kalhor N, Swisher S, Fan Y, Hong WK, Suraokar M, Behrens C, Moran C, Heymach JV.

Oncotarget. 2018 Jan 30;9(18):14268-14284. doi: 10.18632/oncotarget.24361. eCollection 2018 Mar 6.

4.

The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network.

Tan X, Banerjee P, Liu X, Yu J, Gibbons DL, Wu P, Scott KL, Diao L, Zheng X, Wang J, Jalali A, Suraokar M, Fujimoto J, Behrens C, Liu X, Liu CG, Creighton CJ, Wistuba II, Kurie JM.

J Clin Invest. 2018 Apr 2;128(4):1267-1282. doi: 10.1172/JCI97225. Epub 2018 Feb 26. Erratum in: J Clin Invest. 2018 Jul 2;128(7):3198.

5.

Taxane-Platin-Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors.

Dalvi MP, Wang L, Zhong R, Kollipara RK, Park H, Bayo J, Yenerall P, Zhou Y, Timmons BC, Rodriguez-Canales J, Behrens C, Mino B, Villalobos P, Parra ER, Suraokar M, Pataer A, Swisher SG, Kalhor N, Bhanu NV, Garcia BA, Heymach JV, Coombes K, Xie Y, Girard L, Gazdar AF, Kittler R, Wistuba II, Minna JD, Martinez ED.

Cell Rep. 2017 May 23;19(8):1669-1684. doi: 10.1016/j.celrep.2017.04.077.

6.

Expression pattern of FGFR2, Grb2 and Plcγ1 acts as a novel prognostic marker of recurrence recurrence-free survival in lung adenocarcinoma.

Timsah Z, Berrout J, Suraokar M, Behrens C, Song J, Lee JJ, Ivan C, Gagea M, Shires M, Hu X, Vallien C, Kingsley CV, Wistuba I, Ladbury JE.

Am J Cancer Res. 2015 Sep 15;5(10):3135-48. eCollection 2015.

7.

Combined clinical and genomic signatures for the prognosis of early stage non-small cell lung cancer based on gene copy number alterations.

Aramburu A, Zudaire I, Pajares MJ, Agorreta J, Orta A, Lozano MD, Gúrpide A, Gómez-Román J, Martinez-Climent JA, Jassem J, Skrzypski M, Suraokar M, Behrens C, Wistuba II, Pio R, Rubio A, Montuenga LM.

BMC Genomics. 2015 Oct 6;16:752. doi: 10.1186/s12864-015-1935-0.

8.

Genetic mutation of p53 and suppression of the miR-17∼92 cluster are synthetic lethal in non-small cell lung cancer due to upregulation of vitamin D Signaling.

Borkowski R, Du L, Zhao Z, McMillan E, Kosti A, Yang CR, Suraokar M, Wistuba II, Gazdar AF, Minna JD, White MA, Pertsemlidis A.

Cancer Res. 2015 Feb 15;75(4):666-75. doi: 10.1158/0008-5472.CAN-14-1329. Epub 2014 Dec 17.

9.

Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression.

Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA, Zhang X, Yi X, Dwyer D, Lin W, Diao L, Wang J, Roybal J, Patel M, Ungewiss C, Peng D, Antonia S, Mediavilla-Varela M, Robertson G, Suraokar M, Welsh JW, Erez B, Wistuba II, Chen L, Peng D, Wang S, Ullrich SE, Heymach JV, Kurie JM, Qin FX.

Nat Commun. 2014 Oct 28;5:5241. doi: 10.1038/ncomms6241.

10.

Frequent coamplification and cooperation between C-MYC and PVT1 oncogenes promote malignant pleural mesothelioma.

Riquelme E, Suraokar MB, Rodriguez J, Mino B, Lin HY, Rice DC, Tsao A, Wistuba II.

J Thorac Oncol. 2014 Jul;9(7):998-1007. doi: 10.1097/JTO.0000000000000202.

11.

VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapy.

Riquelme E, Suraokar M, Behrens C, Lin HY, Girard L, Nilsson MB, Simon G, Wang J, Coombes KR, Lee JJ, Hong WK, Heymach J, Minna JD, Wistuba II.

Clin Cancer Res. 2014 Jul 15;20(14):3849-61. doi: 10.1158/1078-0432.CCR-13-1916. Epub 2014 May 21.

12.

Elevated PDGFRB gene copy number gain is prognostic for improved survival outcomes in resected malignant pleural mesothelioma.

Tsao AS, Harun N, Fujimoto J, Devito V, Lee JJ, Kuhn E, Mehran R, Rice D, Moran C, Hong WK, Shen L, Suraokar M, Wistuba I.

Ann Diagn Pathol. 2014 Jun;18(3):140-5. doi: 10.1016/j.anndiagpath.2014.02.005. Epub 2014 Feb 20.

13.

Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications.

Suraokar MB, Nunez MI, Diao L, Chow CW, Kim D, Behrens C, Lin H, Lee S, Raso G, Moran C, Rice D, Mehran R, Lee JJ, Pass HI, Wang J, Momin AA, James BP, Corvalan A, Coombes K, Tsao A, Wistuba II.

Ann Oncol. 2014 Jun;25(6):1184-92. doi: 10.1093/annonc/mdu127. Epub 2014 Mar 24.

14.

Radiation-enhanced lung cancer progression in a transgenic mouse model of lung cancer is predictive of outcomes in human lung and breast cancer.

Delgado O, Batten KG, Richardson JA, Xie XJ, Gazdar AF, Kaisani AA, Girard L, Behrens C, Suraokar M, Fasciani G, Wright WE, Story MD, Wistuba II, Minna JD, Shay JW.

Clin Cancer Res. 2014 Mar 15;20(6):1610-22. doi: 10.1158/1078-0432.CCR-13-2589. Epub 2014 Jan 31.

15.

miR-93-directed downregulation of DAB2 defines a novel oncogenic pathway in lung cancer.

Du L, Zhao Z, Ma X, Hsiao TH, Chen Y, Young E, Suraokar M, Wistuba I, Minna JD, Pertsemlidis A.

Oncogene. 2014 Aug 21;33(34):4307-15. doi: 10.1038/onc.2013.381. Epub 2013 Sep 16.

16.

DeMix: deconvolution for mixed cancer transcriptomes using raw measured data.

Ahn J, Yuan Y, Parmigiani G, Suraokar MB, Diao L, Wistuba II, Wang W.

Bioinformatics. 2013 Aug 1;29(15):1865-71. doi: 10.1093/bioinformatics/btt301. Epub 2013 May 27.

17.

A 12-gene set predicts survival benefits from adjuvant chemotherapy in non-small cell lung cancer patients.

Tang H, Xiao G, Behrens C, Schiller J, Allen J, Chow CW, Suraokar M, Corvalan A, Mao J, White MA, Wistuba II, Minna JD, Xie Y.

Clin Cancer Res. 2013 Mar 15;19(6):1577-86. doi: 10.1158/1078-0432.CCR-12-2321. Epub 2013 Jan 28.

18.

BSTA promotes mTORC2-mediated phosphorylation of Akt1 to suppress expression of FoxC2 and stimulate adipocyte differentiation.

Yao Y, Suraokar M, Darnay BG, Hollier BG, Shaiken TE, Asano T, Chen CH, Chang BH, Lu Y, Mills GB, Sarbassov D, Mani SA, Abbruzzese JL, Reddy SA.

Sci Signal. 2013 Jan 8;6(257):ra2. doi: 10.1126/scisignal.2003295.

19.

High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation.

Nunez MI, Behrens C, Woods DM, Lin H, Suraokar M, Kadara H, Hofstetter W, Kalhor N, Lee JJ, Franklin W, Stewart DJ, Wistuba II.

J Thorac Oncol. 2012 May;7(5):833-40. doi: 10.1097/JTO.0b013e31824de09c. Erratum in: J Thorac Oncol. 2012 Jun;7(6):1065.

20.

miR-337-3p and its targets STAT3 and RAP1A modulate taxane sensitivity in non-small cell lung cancers.

Du L, Subauste MC, DeSevo C, Zhao Z, Baker M, Borkowski R, Schageman JJ, Greer R, Yang CR, Suraokar M, Wistuba II, Gazdar AF, Minna JD, Pertsemlidis A.

PLoS One. 2012;7(6):e39167. doi: 10.1371/journal.pone.0039167. Epub 2012 Jun 18.

21.

Immunohistochemical overexpression of platelet-derived growth factor receptor-beta (PDGFR-β) is associated with PDGFRB gene copy number gain in sarcomatoid non-small-cell lung cancer.

Tsao AS, Wei W, Kuhn E, Spencer L, Solis LM, Suraokar M, Lee JJ, Hong WK, Wistuba II.

Clin Lung Cancer. 2011 Nov;12(6):369-74. doi: 10.1016/j.cllc.2011.02.002. Epub 2011 May 17.

22.

TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs.

Su X, Chakravarti D, Cho MS, Liu L, Gi YJ, Lin YL, Leung ML, El-Naggar A, Creighton CJ, Suraokar MB, Wistuba I, Flores ER.

Nature. 2010 Oct 21;467(7318):986-90. doi: 10.1038/nature09459.

23.

Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features.

Solis LM, Behrens C, Dong W, Suraokar M, Ozburn NC, Moran CA, Corvalan AH, Biswal S, Swisher SG, Bekele BN, Minna JD, Stewart DJ, Wistuba II.

Clin Cancer Res. 2010 Jul 15;16(14):3743-53. doi: 10.1158/1078-0432.CCR-09-3352. Epub 2010 Jun 9.

24.

Oleandrin-mediated inhibition of human tumor cell proliferation: importance of Na,K-ATPase alpha subunits as drug targets.

Yang P, Menter DG, Cartwright C, Chan D, Dixon S, Suraokar M, Mendoza G, Llansa N, Newman RA.

Mol Cancer Ther. 2009 Aug;8(8):2319-28. doi: 10.1158/1535-7163.MCT-08-1085. Epub 2009 Aug 11.

25.

Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products.

Kim J, Yang P, Suraokar M, Sabichi AL, Llansa ND, Mendoza G, Subbarayan V, Logothetis CJ, Newman RA, Lippman SM, Menter DG.

Cancer Res. 2005 Jul 15;65(14):6189-98.

26.

Glycogen synthase kinase-3 beta is involved in the phosphorylation and suppression of androgen receptor activity.

Salas TR, Kim J, Vakar-Lopez F, Sabichi AL, Troncoso P, Jenster G, Kikuchi A, Chen SY, Shemshedini L, Suraokar M, Logothetis CJ, DiGiovanni J, Lippman SM, Menter DG.

J Biol Chem. 2004 Apr 30;279(18):19191-200. Epub 2004 Feb 24.

27.

Genetics. Targeting sheep.

Suraokar M, Bradley A.

Nature. 2000 Jun 29;405(6790):1004-5. No abstract available.

PMID:
10890426
28.

p53 deficiency does not affect the accumulation of point mutations in a transgene target.

Sands AT, Suraokar MB, Sanchez A, Marth JE, Donehower LA, Bradley A.

Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8517-21.

Supplemental Content

Loading ...
Support Center